A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile (Q38926456)

7 September 2017

A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile (English)

1 reference

7 September 2017

Mariola Fotin-Mleczek

10

object named as

Mariola Fotin-Mleczek

1 reference

7 September 2017

9

Karl-Josef Kallen

1 reference

7 September 2017

1

Regina Heidenreich

1 reference

7 September 2017

Edith Jasny

2

1 reference

7 September 2017

Aleksandra Kowalczyk

3

1 reference

7 September 2017

Johannes Lutz

4

1 reference

7 September 2017

Jochen Probst

5

1 reference

7 September 2017

Patrick Baumhof

6

1 reference

7 September 2017

Birgit Scheel

7

1 reference

7 September 2017

Söhnke Voss

8

1 reference

7 September 2017

language of work or name

English

0 references

publication date

8 January 2015

1 reference

International Journal of Cancer

7 September 2017

1 reference

7 September 2017

137

1 reference

7 September 2017

2

1 reference

7 September 2017

372-384

1 reference

MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates

7 September 2017

1 reference

The perfect mix: recent progress in adjuvant research

21 January 2018

1 reference

Trial Watch: Experimental Toll-like receptor agonists for cancer therapy

21 January 2018

1 reference

Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy

21 January 2018

1 reference

Adjuvants that improve the ratio of antigen-specific effector to regulatory T cells enhance tumor immunity.

21 January 2018

1 reference

Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909.

21 January 2018

1 reference

Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer.

21 January 2018

1 reference

CpG ODN nanorings induce IFNα from plasmacytoid dendritic cells and demonstrate potent vaccine adjuvant activity.

21 January 2018

1 reference

Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus

21 January 2018

1 reference

Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans

21 January 2018

1 reference

Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA

21 January 2018

1 reference

Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8

21 January 2018

1 reference

Boosting with recombinant vaccinia increases HPV-16 E7-Specific T cell precursor frequencies and antitumor effects of HPV-16 E7-Expressing sindbis virus replicon particles

21 January 2018

1 reference

Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6.

21 January 2018

1 reference

Granzyme A is an interleukin 1 beta-converting enzyme

21 January 2018

1 reference

Caspase 1-independent activation of interleukin-1beta in neutrophil-predominant inflammation

21 January 2018

1 reference

Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta

21 January 2018

1 reference

Towards an understanding of the adjuvant action of aluminium

21 January 2018

1 reference

Aluminium compounds for use in vaccines

21 January 2018

1 reference

Regulation of effector and memory T-cell functions by type I interferon

21 January 2018

1 reference

Effects of IFN-α as a signal-3 cytokine on human naïve and antigen-experienced CD8(+) T cells

21 January 2018

1 reference

IFN-α produced by human plasmacytoid dendritic cells enhances T cell-dependent naïve B cell differentiation

21 January 2018

1 reference

Regulation of inflammasome activity.

21 January 2018

1 reference

Molecular and cellular signatures of human vaccine adjuvants.

21 January 2018

1 reference

Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action

21 January 2018

1 reference

Critical role of an antiviral stress granule containing RIG-I and PKR in viral detection and innate immunity

21 January 2018

1 reference

Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans

21 January 2018

1 reference

HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial

21 January 2018

1 reference

Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia

21 January 2018

1 reference

Combination adjuvants: the next generation of adjuvants?

21 January 2018

1 reference

Programming the magnitude and persistence of antibody responses with innate immunity

21 January 2018

1 reference

Efficient induction of anti-tumor immunity by a TAT-CEA fusion protein vaccine with poly(I:C) in a murine colorectal tumor model.

21 January 2018

1 reference

Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance

21 January 2018

1 reference

Combined immunization with adjuvant molecules poly(I:C) and anti-CD40 plus a tumor antigen has potent prophylactic and therapeutic antitumor effects

21 January 2018

1 reference

In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to Freund's complete adjuvant, but continues to induce T helper 2 cytokine production

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.29402

1 reference

7 September 2017

1 reference